

---

**CONTENTS**

1. Introduction
  - 1.1 Introduction
  - 1.2 Aims and objectives
  - 1.3 Hypothesis
  - 1.4 Plan of work
  - 1.5 References
2. Literature review
  - 2.1 Anatomy and Physiology of Human Uterus
    - 2.1.1 Structure of Human Uterus
    - 2.1.2 Uterine Vascular system
  - 2.2 First Uterine Pass Effect
  - 2.3 Uterine Fibroids and Endometriosis
    - 2.3.1 Uterine Fibroids
    - 2.3.2 Endometriosis
  - 2.4 Management and Treatment of Uterine Fibroids and Endometriosis
    - 2.4.1 Surgical Treatment
    - 2.4.2 Medical Treatment
    - 2.4.3 Ablative Therapy
  - 2.5 Targeted Drug Delivery Systems
    - 2.5.1 Types of Targeted Drug Delivery
      - 2.5.1.1 Passive Targeting
      - 2.5.1.2 Active Targeting
    - 2.5.2 Carriers for Targeted Drug Delivery Systems
      - 2.5.2.1 Inorganic Nanoparticles
      - 2.5.2.2 Polymeric Micelles
      - 2.5.2.3 Dendrimers
      - 2.5.2.4 Carbon Nanotubes
      - 2.5.2.5 Liposomes

---

- 2.6 Vaginal Drug Delivery
  - 2.6.1 Mucoadhesive Formulations
  - 2.6.2 Mechanical Fixation
    - 2.6.2.1 Tablets and Discs
    - 2.6.2.2 Intravaginal Rings
- 2.7 In Vivo Biodistribution Study by Gamma Scintigraphy
- 2.8 Review of the past work done
  - 2.8.1 Review of the past work done on Leuprolide acetate
  - 2.8.2 Review of the past work done on Raloxifene Hydrochloride
- 2.9 Drug Profile
  - 2.9.1 Leuprolide acetate
  - 2.9.2 Raloxifene Hydrochloride
- 2.10 Excipient Profile
  - 2.10.1 DSPC: 1,2-Distearoyl-sn-glycero-3-phosphocholine
  - 2.10.2 Cholesterol
- 2.11 References
- 3. Analytical methods
  - 3.1 Introduction
  - 3.2 Materials and Equipment
  - 3.3 Analytical Methods for estimation of Leuprolide acetate
    - 3.3.1 UV-Visible Spectrophotometric Method in Distilled Water
    - 3.3.2 UV-Visible Spectrophotometric Method in SVF pH 4.2
    - 3.3.3 Method Validation
      - 3.3.3.1 Linearity
      - 3.3.3.2 Accuracy
      - 3.3.3.3 Precision
      - 3.3.3.4 LOD and LOQ
    - 3.3.4 Analytical Interference Study
    - 3.3.5 Estimation of Leuprolide acetate in Rabbit plasma using LCMS-MS method
  - 3.4 Analytical Methods for estimation of Raloxifene Hydrochloride
    - 3.4.1 UV-Visible Spectrophotometric Method in Methanol: Chloroform (1:9)
    - 3.4.2 UV-Visible Spectrophotometric Method in SVF pH 4.2
    - 3.4.3 Method Validation

---

- 
- 3.4.3.1 Linearity
  - 3.4.3.2 Accuracy
  - 3.4.3.3 Precision
  - 3.4.3.4 LOD and LOQ
  - 3.4.4 Analytical Interference Study
  - 3.4.5 Estimation of Raloxifene Hydrochloride in Rabbit plasma using LCMS-MS method
  - 3.5 Analytical Method for simultaneous estimation of Leuprolide acetate and Raloxifene Hydrochloride in SVF pH 4.2
  - 3.6 Results and Discussion
  - 3.7 References
  - 4. Preformulation studies and Preliminary Optimization
    - 4.1 Introduction
    - 4.2 Materials and Equipment
    - 4.3 Preformulation studies
      - 4.3.1 Methods
      - 4.3.2 Results and Discussion
    - 4.4 Preliminary Optimization of Formulation Parameters
      - 4.4.1 Type of Lipid
      - 4.4.2 Volume of Hydration media
    - 4.5 Preliminary Optimization of Process Parameters
    - 4.6 References
  - 5. Formulation Development
    - 5.1 Introduction
    - 5.2 Materials and Equipment
    - 5.3 Preparation and Optimization of Raloxifene Hydrochloride loaded Liposomes
      - 5.3.1 Preparation of liposomal formulation and optimization by Design of Experiment
        - 5.3.1.1 Determination of Vesicle size
        - 5.3.1.2 Determination of % Entrapment Efficiency
        - 5.3.1.3 Checkpoint analysis
      - 5.3.2 Results and Discussion for Formulation and Optimization of RLX-Loaded Liposomes

---

5.3.2.1	Statistical evaluation of results of vesicle size
5.3.2.2	Statistical evaluation of results of % EE
5.3.2.3	Results of Checkpoint Analysis
5.4	Preparation and Optimization of Leuprolide acetate loaded Liposomes
5.4.1	Preparation of liposomal formulation and optimization by Design of Experiment
5.4.1.1	Determination of Vesicle size
5.4.1.2	Determination of % Entrapment Efficiency
5.4.1.3	Checkpoint analysis
5.4.2	Results and Discussion for Formulation and Optimization of LA-Loaded Liposomes
5.4.2.1	Statistical evaluation of results of vesicle size
5.4.2.2	Statistical evaluation of results of % EE
5.4.2.3	Results of Checkpoint Analysis
5.5	Preparation and Optimization of dual drug loaded Liposomes
5.5.1	Preparation of liposomal formulation and optimization by Design of Experiment
5.5.1.1	Determination of Vesicle size
5.5.1.2	Determination of % Entrapment Efficiency
5.5.1.3	Checkpoint analysis
5.5.2	Results and Discussion for Formulation and Optimization of RLX-LA-Loaded Liposomes
5.5.2.1	Statistical evaluation of results of vesicle size
5.5.2.2	Statistical evaluation of results of % EE
5.5.2.3	Results of Checkpoint Analysis
5.6	Preparation of liposomal formulations loaded Rod Insert-Intravaginal Rings
5.7	References
6.	Characterization of Formulations
6.1	Introduction
6.2	Materials and Equipment
6.3	Methods
6.3.1	Vesicle size
6.3.2	Zeta potential

---

- 
- 6.3.3 % Entrapment Efficiency
  - 6.3.4 Drug Loading (%w/w)
  - 6.3.5 Morphological analysis by TEM and SEM
  - 6.3.6 In Vitro Drug Release Study
  - 6.4 Results and discussion
    - 6.4.1 Vesicle size
    - 6.4.2 Zeta potential
    - 6.4.3 % Entrapment Efficiency
    - 6.4.4 Drug Loading (%w/w)
    - 6.4.5 Morphological analysis by TEM and SEM
    - 6.4.6 In Vitro Drug Release
      - 6.4.6.1 Drug Release from Liposomal Formulations
      - 6.4.6.2 Drug Release from Intra Vaginal Rod Inserts
  - 6.5 References
  - 7. Ex Vivo Histopathology Study
    - 7.1 Introduction
    - 7.2 Materials
    - 7.3 Method
    - 7.4 Results and Discussion
    - 7.5 References
  - 8. In Vitro Cell Cytotoxicity Study
    - 8.1 Introduction
      - 8.1.1 Cytotoxicity study by MTT Assay
      - 8.1.2 Cell Cycle Analysis and Apoptosis Study
    - 8.2 Materials and Equipment
    - 8.3 MTT Assay
    - 8.4 Apoptosis and Cell Cycle Analysis by FACS
    - 8.5 Results and Discussion
      - 8.5.1 Results of MTT Assay
      - 8.5.2 Results of Apoptosis and Cell Cycle Analysis
    - 8.6 References
  - 9. In Vivo Biodistribution Study
    - 9.1 Introduction

---

9.2	Materials and Equipment
9.3	Radiolabeling of Drugs
9.3.1	Radiolabeling of Raloxifene Hydrochloride
9.3.2	Radiolabelling of Leuprolide acetate
9.4	Quality Control Tests
9.4.1	pH of the Radiolabeled Drugs
9.4.2	Determination of Radiolabeling efficiency
9.4.3	Stability of Radiolabeled Complex in serum and normal saline
9.4.4	Transchelation Study (DTPA Challenge)
9.5	Biodistribution Study
9.5.1	Biodistribution study of radiolabeled RLX loaded Liposomes
9.5.2	Biodistribution study of radiolabeled LA loaded Liposomes
9.6	Results and Discussion
9.6.1	Results of pH of the Radiolabeled Drugs
9.6.2	Results of Determination of Radiolabeling efficiency
9.6.2.1	Radiolabeling efficiency of RLX
9.6.2.2	Radiolabeling efficiency of LA
9.6.3	Results of Stability of Radiolabeled Complex in serum and normal saline
9.6.3.1	Stability of $^{99m}\text{Tc}$ -RLX complex
9.6.3.2	Stability of $^{99m}\text{Tc}$ -LA complex
9.6.4	Results of Transchelation Study (DTPA Challenge)
9.6.5	Results of Biodistribution Study
9.6.5.1	Results of Biodistribution Study of $^{99m}\text{Tc}$ -RLX loaded Liposomes
9.6.5.2	Results of Biodistribution Study of $^{99m}\text{Tc}$ -LA loaded Liposomes
9.7	References
10	In Vivo Pharmacodynamic and Pharmacokinetic Study
10.1	Introduction
10.2	Materials and Equipment
10.3	Pharmacodynamic Study
10.3.1	Induction of Uterine Fibroids in Rabbits
10.3.2	Tumour Regression analysis by Ultrasonography
10.4	Pharmacokinetic Study
10.5	Results and Discussion

10.5.1 Results of Pharmacodynamic Study

10.5.2 Results of Pharmacokinetic Study

10.6 References

11 Stability Study

11.1 Introduction

11.2 Materials and Equipment

11.3 Method

11.4 Results and Discussion

11.5 References

12 Summary and Conclusion

12.1 Summary

12.2 Conclusion